These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11552628)

  • 21. Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders.
    de Kemp EC; Moleman P; Hoogduin CA; Broekman TG; Goedhart A; Schaap CP; van den Berg PC
    Psychopharmacology (Berl); 2002 Feb; 160(1):67-73. PubMed ID: 11862375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suicidal risk during controlled clinical investigations of fluvoxamine.
    Letizia C; Kapik B; Flanders WD
    J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
    Judge R; Wagner BE
    J Clin Psychiatry; 1999 Nov; 60(11):795-6. PubMed ID: 10584775
    [No Abstract]   [Full Text] [Related]  

  • 24. Full efficacy of SSRI treatment in refractory dysthymia is achieved only after 16 weeks.
    Albert R; Ebert D
    J Clin Psychiatry; 1996 Apr; 57(4):176. PubMed ID: 8601556
    [No Abstract]   [Full Text] [Related]  

  • 25. [The use of antidepressants to treat depression in children and adolescents].
    Desombre H; Paccalin C; Revol O; Fourneret P
    Arch Pediatr; 2006 Jun; 13(6):711-3. PubMed ID: 16697608
    [No Abstract]   [Full Text] [Related]  

  • 26. [Anxiety and depression: which antidepressants treat both at the same time?].
    Laflamme F
    Perspect Infirm; 2010; 7(2):43. PubMed ID: 21744603
    [No Abstract]   [Full Text] [Related]  

  • 27. [A comparative clinical evaluation of the antidepressive activity of fluoxetine and fluvoxamine].
    Lopukhov IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(4):53-7. PubMed ID: 9214192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Additional treatment in chronic pain syndrome due to hip and knee arthritis with the selective serotonin reuptake inhibitor fluvoxamine (Fevarin].
    Riesner HJ; Zeitler C; Schreiber H; Wild A
    Z Orthop Unfall; 2008; 146(6):742-6. PubMed ID: 19085723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivors of torture presenting at an anxiety disorders clinic: symptomatology and pharmacotherapy.
    Bouwer C; Stein DJ
    J Nerv Ment Dis; 1998 May; 186(5):316-8. PubMed ID: 9612450
    [No Abstract]   [Full Text] [Related]  

  • 30. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Care of depressed patients with anxiety symptoms.
    Nutt DJ
    J Clin Psychiatry; 1999; 60 Suppl 17():23-7; discussion 46-8. PubMed ID: 10446738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute therapy of depression.
    Bech P
    J Clin Psychiatry; 1993 Aug; 54 Suppl():18-27; discussion 28. PubMed ID: 8253702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors.
    Papakostas GI; Fan H; Tedeschini E
    Eur Neuropsychopharmacol; 2012 May; 22(5):347-55. PubMed ID: 22099607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of patients with depression associated with anxiety symptoms.
    Nutt D
    J Clin Psychiatry; 1997; 58 Suppl 8():11-6. PubMed ID: 9236730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA
    Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.
    Serretti A; Zanardi R; Rossini D; Cusin C; Lilli R; Smeraldi E
    Mol Psychiatry; 2001 Sep; 6(5):586-92. PubMed ID: 11526473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. If a patient does not respond to a full dose of fluvoxamine for at least 12 weeks, what alternatives should be considered?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.